Abstract | PURPOSE: PATIENTS AND METHODS: From December 1997 to February 1999, 78 chemotherapy-naive patients (median age 60 years, Karnofsky performance status of 100, 90, 80 and 70 present in 5%, 41%, 36% and 18% of the patients, respectively) with stage IIIB (17%) or IV (83%) NSCLC (65% adenocarcinomas, 22% squamous-cell carcinomas, 10% large-cell carcinomas, 3% mixed-cell carcinomas) received 25 mg/m2 vinorelbine and 1200 mg/m2 gemcitabine on days 1, 8 and 15 of a four-week cycle. RESULTS: In an intent-to-treat analysis, partial responses were seen in 19% of the patients. The median duration of response was 4.4 months. The median survival time was seven months and the one-year survival rate was 32%. Myelosuppression was the main side effect with WHO grade 3/4 neutropenia and thrombocytopenia in 35% and 11% of the patients, respectively. Other side effects were usually mild to moderate. CONCLUSIONS:
Vinorelbine- gemcitabine is active, well tolerated and easy to administer on an outpatient basis in advanced NSCLC. Thus a randomized comparison of this combination with platinum-based protocols is warranted in patients with advanced NSCLC.
|
Authors | G Krajnik, A Mohn-Staudner, J Thaler, R Greil, S Schmeikal, F Marhold, J Deutsch, P Preiss, R Malayeri, C Schäfer-Prokop, W Wein, H Huber, R Pirker |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 11
Issue 8
Pg. 993-8
(Aug 2000)
ISSN: 0923-7534 [Print] England |
PMID | 11038036
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Deoxycytidine
- Vinblastine
- Vinorelbine
- Gemcitabine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Female
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Neutropenia
(chemically induced)
- Survival Analysis
- Treatment Outcome
- Vinblastine
(administration & dosage, analogs & derivatives)
- Vinorelbine
- Gemcitabine
|